{"title": null, "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2020-12-18", "cleaned_text": "El Grupo de Vigilancia e Inteligencia de la Empresa de Tecnolog\u00edas de la Informaci\u00f3n perteneciente a BioCubaFarma pone a su disposici\u00f3n el presente bolet\u00edn en aras de mantenerlo informado sobre la situaci\u00f3n de la pandemia Covid-19 desde el punto de vista cient\u00edfico como divulgativo, a partir de la recopilaci\u00f3n de informaci\u00f3n en fuentes validadas, contribuyendo as\u00ed a evitar las falsas noticias. En sus contenidos se pueden encontrar datos que ofrecen los organismos nacionales e internacionales, informaci\u00f3n cient\u00edfica y una actualizaci\u00f3n semanal de la situaci\u00f3n epidemiol\u00f3gica en Cuba y a nivel mundial. Este bolet\u00edn es el resultado de la monitorizaci\u00f3n autom\u00e1tica a trav\u00e9s de la plataforma Vigintel de fuentes de informaci\u00f3n validadas de acceso p\u00fablico relacionadas con la Covid-19. Entre las secciones que incluyen: - Actualizaci\u00f3n de la situaci\u00f3n epidemiol\u00f3gica de Cuba y a nivel internacional. - Informaci\u00f3n cient\u00edfica, como: ensayos cl\u00ednicos, art\u00edculos cient\u00edficos. - Noticias destacadas de medios de difusi\u00f3n nacionales e internacionales, incluyendo aquellas resaltadas por el portal Infomed y de diferentes organismos de referencia. Cualquier persona o instituci\u00f3n interesada en aportar informaci\u00f3n o documentaci\u00f3n a este Bolet\u00edn, puede remitirlo a vigintel@eti.biocubafarma.cu. 2020-12-25 19:40 |RESUMEN SEMANAL| En Cuba, contin\u00faa el incremento de los casos importados y el pa\u00eds ha llegado a tener una tasa de incidencia de 77 por 100 000 habitantes (no incluye los casos importados). En los \u00faltimos 15 d\u00edas se han confirmado 885 casos, para una tasa de 7,90 por 100 000 habitantes. |ACTUALIZACI\u00d3N EPIDEMIOL\u00d3GICA| use diagnosis codes for novel coronavirus patients in January-May 2020, before and afer the April 1 release of the U07.1 code to facilitate billing for and case monitoring of Administrative claims provide an understanding of the clinical and economic burden of novel coronavirus disease 2019 (COVID-19). their limited in identifying conditions, such as sepsis, A new facilitate billing and case monitoring. This and stressor type subgroups. We fielded wave 2 of the Johns Hopkins COVID-19 Civic Life and Public Health Survey from July 7 to July 22, 2020, among US adults aged 18 years and older who responded to wave 1, fielded April 7 to 13, 2020. The sample was NORC's from NORC's area probability Service sample 97% of diagnosis, and management of the arterial and venous thrombotic complications. In a US registry of patients disease 2019 (COVID-19), thrombotic 170 hospitalized critically ill patients. |ART\u00cdCULOS RECUPERADOS DE LA BASE DE DATOS WHO COVID-19| Secondary bacterial and fungal infections are associated with infections and invasive mechanical ventilation. In Coronavirus SARS-CoV-2 and impaired immune response can provide a individuals. Recent studies suggest that secondary bacterial pneumonia is a risk factor associated with COVID-19. In Brazil, knowledge about microbiota present in COVID-19 patients is incipient. This work describes the microbiota of 21 interconnection between bacterial presence in COVID-19 progression are discussed. Background: The propagation of COVID-19 in Spain prompted the declaration of the state of alarm on March 14, 2020. On 2 December 2020, the infection had been professionals involved. Decision support systems in clinical care and health services management were identified as crucial in the fight against the pandemic. Methods: This study applies Deep Learning techniques COVID-19 patients. Two datasets with clinical information (medication, laboratory tests, vital etc.) of 2,307 and 3,870 COVID-19 infected patients admitted to two Spanish hospital chains were used. Firstly, we built a sequence of temporal events gathering all the clinical information for each patient. Next, we used the temporal sequences to train the performance of our models using both global metrics, by averaging the performance across all days in the sequences. We also measured day-by-day metrics starting from the day of hospital admission and the outcome day and evaluated the daily predictions. Regarding sensitivity, when compared to more traditional models, our best two RNN ensemble models outperform a Support Vector Classifier in 6 and 16 percentage points, and Random Forest in 23 and 18 points. For the day-by-day predictions from the outcome predict the of patients infected with SARS-CoV-2. The result is a time series model that can support decision-making in healthcare systems and that more data will further increase the performance of the model. Romania officially declared its first SARS-CoV-2 case on February 26, 2020. The first and largest COVID-19 outbreak in Romania was recorded in Suceava, N/E region of the country, and originated at the regional county hospital. Following sheltering-in-place rates decreased, only to rise of This study describes the incursion of SARS-CoV-2 in Suceava and other parts of Romania and analyzes the mutations and their association with clinical manifestation of the disease during the period of COVID-19 analysis of Suceava, Italy and Russia, but also other strains related to those from Czech Republic, Belgium and France. Suceava samples possible different origin. overall genome regions ORF1ab, and were recurring mutations such as C27707T identified, and a protein responsible for decreasing viral tethering in human host were also present. Patients with diabetes hypertension exhibited coronavirus, is currently generating a global pandemic Vaccine development is no doubt the best long-term immunological approach, but in the current epidemiologic and health emergency there is a need for rapid and effective solutions Convalescent plasma is the only antibody-based (EpAbs) put forward a to manufacture allowing a fast development and scaling up for a treatment Based on these ideas, we present a new therapeutic product obtained after immunization of horses with the receptor-binding domain of the viral Spike glycoprotein Our product shows around 50 times more potency in in vitro seroneutralization assays than the average of convalescent plasma This result may allow us to test the safety and efficacy of this product in a phase 2/3 clinical trial to be conducted in July 2020 in the metropolitan area of Buenos Aires, Argentina La enfermedad denominada COVID-19 es causada por el coronavirus SARS-CoV-2 y es actualmente considerada una pandemia a nivel global El desarrollo de vacunas es sin duda la mejor estrategia a largo plazo, pero debido a la emergencia sanitaria, existe una necesidad urgente de encontrar soluciones r\u00e1pidas y efectivas para el tratamiento de la enfermedad Hasta la fecha, el uso de plasma de convalecientes es la \u00fanica inmunoterapia disponible para pacientes hospitalizados con COVID-19 El uso de anticuerpos policlonales equinos (EpAbs) es otra alternativa terap\u00e9utica interesante La nueva generaci\u00f3n de EpAbs incluyen el procesamiento y purificaci\u00f3n de los mismos y la obtenci\u00f3n de fragmentos F(ab)2 con alta pureza y un excelente perfil de seguridad en humanos Los EpAbs son f\u00e1ciles de producir, lo cual permite el desarrollo r\u00e1pido y la elaboraci\u00f3n a gran escala de un producto terap\u00e9utico En este trabajo mostramos el desarrollo de un suero terap\u00e9utico obtenido luego de la inmunizaci\u00f3n de caballos utilizando el receptor-binding domain de la glicoprote\u00edna Spike del virus Nuestro producto mostr\u00f3 ser alrededor de 50 veces m\u00e1s potente en ensayos de seroneutralizaci\u00f3n in vitro que el promedio de los plasmas de convalecientes Estos resultados nos permitir\u00edan testear la seguridad y eficacia de nuestro producto en ensayos cl\u00ednicos de fase 2/3 a realizarse a partir de julio de 2020 en la zona metropolitana de Buenos Aires, Argentina The novel coronavirus pneumonia (NCP) outbreak occurred in Wuhan, China at the end of 2019 Here, we report the clinical characteristics and therapeutic procedure for a started on After the symptoms improved, and the status was confirmed as NCP negative Our results may provide clues Sixty-two cases receiving favipiravir treatment for at and treatment RESULTS The mean age of the patients receiving treatment 7\u00b112 3 years Nasopharyngeal swab positivity was in comorbid conditions detected in patients were hypertension in 25 cases (40 3%) and diabetes in 16 cases (25 8%) In the statistical analysis of the hematological parameters before and after treatment with favipiravir, were found to be unaffected;the mean RBC was found to have decreased from 4 33 \u00b1 0 58 M/uL to 4 16 \u00b1 0 54 M/uL (p:0 003);the median hemoglobin level was found to have 3 g/dl to 11 9 g/dl (p:0 041);the hematocrit level decreased from 38 1% \u00b1 4 8 to 36 9% \u00b1 4 2 (p:0 026);the median neutrophil count decreased (p:0 001);the mean lymphocyte count increased from 1 22 \u00b1 0 53 K/uL to 1 84 \u00b1 1 19 K/uL (p:0 000);and the mean platelet count increased from 244 1 \u00b1 85 1 K/uL to 281 9 \u00b1 103 3 K/uL (p:0 005) CONCLUSION We concluded that the pathological effect of treatment with favipiravir on the hematologic system was the suppression in the erythrocyte series, and there were no in other parameters dois casos em tratamento com favipiravir por pelo cinco devido nos pacientes foram hipertens\u00e3o em 25 casos (40,3%) e diabetes em 16 casos (25,8%) Na an\u00e1lise estat\u00edstica par\u00e2metros focusing SARS-CoV-2 spike protein and the nucleoprotein in a COVID-19 infection. Now it is popular all over the world on a large scale. COVID-19 has the characteristics of rapid transmission, atypical clinical symptoms, easy missed misdiagnosis, and so on. which has seriously affected social and economic development and people's health. Severe respiratory syndrome systemic cytokine storm, which leads to a sharp deterioration of the condition of ordinary patients. At present, no specific drug has been found in the clinical treatment of covid-19, while Xuebijing injection has been widely used in severe patients in China as a traditional Chinese medicine. The aim of this study is to assess the effificacy and safety of Xuebijing injection for COVID-19. The aims of this meta-analysis were to assess: 1) the prevalence of coronavirus disease 2019 (COVID-19) in hip fracture patients; 2) the associated mortality rate and risk associated with COVID-19; 3) the patient demographics associated with COVID-19; 4) time of diagnosis; and 5) length of follow-up after diagnosis of COVID-19. CONCLUSION: The prevalence of COVID-19 was 13%, of which approximately one-third of patients were diagnosed on admission, and had a crude mortality rate of 35%, being seven times greater than those without COVID-19. Due to the heterogenicity of the reported data minimum reporting standards of outcomes associated with COVID-19 are suggested. Cite this article: Bone Joint Res Cochrane for Systematic PubMed, 28 L, Mazzoni A, Maggi L, Capone M, Parronchi P, Liotta F, Miele V, F, Rep. 2020 12 11;10(1):21775 Authors: Landi L, Ravaglia C, Russo D, Facondini I, Lazzari-Agli L, Bassi P, Marchionni E, Romagnoli R, De Giovanni R, Assirelli M, Baldazzi F, Pieraccini F, Rametta G, Rossi L, L, I, screening COVID-19. PLoS One. 2020;15(12):e0243692 Authors: T, Pfl\u00fcger to ARDS. as diffuse alveolar damage in and cells is a critical feature of examined apoptosis in post-mortem lung sections from COVID-19 patients and lung tissues from a non-human model of SARS-CoV-2 infection, in a cell-type manner, including type 1 and 2 alveolar cells and vascular endothelial cells (ECs), macrophages, and T cells. Multiple-target immunofluorescence SARS-CoV-2 induced apoptosis in both Vero cells and HUVECs/BEAS2B cells, but did not alter the permissiveness of HUVECs or BEAS2B cells to the virus. Post-exposure treatment of the co-culture of Vero cells pandemic disease 2019 (COVID-19) is now the greatest threat to the global public health. Herbal medicines and their derived natural products have drawn much attention to treat COVID-19, but there has been no natural showing inhibitory activity against SARS-CoV-2 infection commonly used East Asia, effectively blocks the agent. Furthermore, study proposes that a potent natural product for preventing or treating COVID-19 and that a brief disruption of repurposed drugs, preclinical drug a cardiac azithromycin QT interval from day 6 onwards. AZM alone elicited an increase in QT interval from day 7 onwards and arrhythmias were observed for negative QT prolongation and rhythm instabilities. representative hospital surveillance system South Africa. Methods: A national surveillance system laboratory-confirmed COVID-19 hospital admissions private hospitals with COVID-19 during 5 March to 11 August 2020. Multivariable logistic regression models were used to compare Increased mortality was associated with HIV and TB, as well as other described risk factors for COVID-19, such as increasing age, male sex, non-White was 39.9%. The effect of multiple HIV-infected -uninfected individuals. These HIV presence of chronic (particularly hypertension diabetes) are with COVID-19 mortality in a from COVID-19 prevention and treatment programmes. a have been described on the status of the immune system of patients infected with SARS-CoV-2, but there are still aspects that have not been fully characterized. In this study, we have analyzed a cohort cell of granzyme B in cells, expansion of adaptive NK cells and the accumulation of activated and immature dysfunctional monocytes which are expression and an association the alterations in the immune cells and the clinical signs of severity. These results indicate that patients with severe COVID-19 have a broad perturbation of their immune system, and they will help to understand the immunopathogenesis of severe COVID-19 as well as could be of special value for physicians to decide which specific therapeutic options are effective in of with central (CNS) and peripheral nervous (PNS) system manifestations are emerging. In To our knowledge, this is among the first reviews that includes GBS variants and also crucial time identify the well treatment complementary treatment of viral diseases and recently suggested for the treatment of COVID-19. In the present study, we investigated aqueous licorice highlight glycyrrhizin as a potential antiviral compound that should be further investigated for the treatment of COVID-19. Background: to engage with its receptors and infect host cells. To date, it is still not known if the S protein alone, without the other viral elements, is able S protein signalling in PCs. Findings: We show, for the first time, that the recombinant S protein alone elicits functional alterations migration, (2) reduced ability to responsible death. Furthermore, rescued function in presence of the protein. Interpretation: Our findings suggest the new, amplifying, or damage by This mechanism between treatment with (vs. without) renin-angiotensin system risk or in combination with azithromycin (AZM) in the management of the emerging coronavirus. This systematic review and meta-analysis of either mechanical ventilation (MV), virologic cure rate (VQR), time to employment, alcohol use, diet and obesity, access to medical care. These are some of the factors causing worse cancer outcomes in people factors are also causing worse outcomes Patients with have immunoglobulin G (IgG) within 3 weeks after infection. No data are available on the seroconversion rates of patients and patients higher of severe events and unfavourable outcomes in the setting of COVID-19. This review directly address COVID-19 testing of asymptomatic patients before treatment. Our systematic review showed that most of the published data favours routine test for SARS-CoV-2 before initiating systemic treatment but failed to identify a good level of evidence to support these recommendations. Based upon this review, we proposed local recommendations at our centre. Each institution should consider the pros cons disease (COVID)-19 mortality around 5%. Information in pediatric cancer patients is still limited, but it is emerging day by day. The objective of this scoping review was to analyze the available data associated with COVID-19 infection pediatric cancer patients design strategies in this group. CONCLUSIONS: Given the nature reports and a short in cancer to to effects to the treatments of and neck squamous cell carcinoma (HNSCC) is increasing worldwide, with over three quarters of cases now diagnosed low and and survival. is high-quality evidence that intensification of treatment by either by adding concurrent chemotherapy or altering radiotherapy expressing the of live vaccine candidate. EBioMedicine. 2020 Dec;62:103132 Authors: Sun W, Leist SR, McCroskery Liu Y, Oliva Authors: Guo J, Wan X, Zhou JG, Jin WP, Lu J, Wang WH, Yang AN, Liu DX, Shi ZL, Yuan ZM, Li XG, Meng SL, Duan K, MEDLINE] |PREVALENCIA Y SEROPREVALENCIA| Background In spring 2020, at the beginning of the first pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wave in Europe, we set up an assay system for large-scale testing of virus-specific and protective antibodies including their longevity. Methods We employees for SARS-CoV-2-specific antibodies using the the results at 0, three and six months. Findings We found immunoglobulin G (IgG) NT (kappa = 0.9448) and only these antibodies were stable for up to six months. All with HCoV. indentified C-terminus SARS-CoV2 N of minimal sequence that in and longer symptoms and females. remained declined and HCoV crossreactive antibodies, both of may affect the acquisition of immunity to COVID-19. Introduction The public health measures imposed to contain Covid-19 during the first UK significant changes in the provision of community support and care for people with dementia. People with low prevalence the impact of the first Covid-19 lockdown on people living with low prevalence and young-onset dementia and their carers in the UK. Method An online survey, including eleven questions about the impact of the lockdown on both the person with dementia and their family caregivers was conducted. Participants were people living with dementia and caregivers who are members of the UK national-reach organisation Rare Dementia Support. Results 184 carers and 24 people with dementia completed the survey. People with dementia experienced worsening of cognitive symptoms (70%), ability to caring (55%). 93% of carers of people living in care homes reported a reduction in their ability to provide care. 26% carers the person people to connect with people experienced a removal of support increased connect with other people socially during the wave of Covid-19. Carers encountered both receiving and providing support and a decline in their own mental health and well-being. Objective: This study aimed to determine the frequency of SARS-CoV-2 RNA in serum and its association with the clinical severity of COVID-19. Methods: An analytical cross-sectional study was performed in a single tertiary care hospital and included consecutive patients with confirmed COVID-19. The prevalence of SARS-CoV-2 in study. The median age was 54.5 years, and individuals with RNAemia were older than those without detectable SARS-CoV-2 RNA in serum (78 vs. 50 years; P RNAemia loads of NP swabs that were collected around the same time as the serum were significantly NP tests as indicator for COVID-19 with |NOTICIAS EMITIDAS| |DESTACADAS DE LA SEMANA| El Gobierno cubano continu\u00f3 adoptando acciones para incrementar las medidas de contenci\u00f3n ante la COVID-19, con casos generados principalmente por nacionales procedentes del extranjero, por los contactos de estos \u2014que son mayoritariamente sus familiares\u2014, y por personas contagiadas por estos \u00faltimos.A partir del 10 de enero todos los viajeros que lleguen al pa\u00eds deber\u00e1n portar un PCR en tiempo real realizado como m\u00e1ximo 72 horas antes por laboratorios certificados de los pa\u00edses de origen. La nueva cepa del COVID-19 es entre 50 y 74% m\u00e1s contagiosa afirm\u00f3 un estudio m\u00e9dico que advirti\u00f3 sobre sus consecuencias en Reino Unido. La aparici\u00f3n de una nueva cepa del coronavirus en Reino Unido caus\u00f3 p\u00e1nico en todo el mundo, provocando que una decena de capitales cancelaran vuelos con el pa\u00eds, que qued\u00f3 aislado. Sin embargo, la Organizaci\u00f3n Mundial de la Salud (OMS) intent\u00f3 dar un mensaje tranquilizador, afirmando que la nueva cepa del virus \"no est\u00e1 [...] El fundador y presidente de la empresa alemana Biontech, Ugur Sahin, indic\u00f3 que la vacuna contra el coronavirus desarrollada por su compa\u00f1\u00eda junto con Pfizer probablemente sea eficaz contra la nueva cepa detectada en Gran Breta\u00f1a, en declaraciones recientes. \"Ya hemos probado la vacuna contra otras 20 mutaciones del virus y la respuesta inmune que [...] |DESTACADAS DE INFOMED| Otra nueva variante del coronavirus parece haber aparecido en Nigeria, seg\u00fan indic\u00f3 recientemente el m\u00e1ximo responsable de salud p\u00fablica en \u00c1frica, aunque hace falta m\u00e1s investigaci\u00f3n. El descubrimiento podr\u00eda ser otro motivo de alarma en la pandemia, despu\u00e9s de que se identificaran otras variantes en Gran Breta\u00f1a y Sud\u00e1frica que provocaron un regreso de las [...] Un nuevo informe de la Asociaci\u00f3n Espa\u00f1ola contra el C\u00e1ncer confirma un secreto a voces: el n\u00famero de diagn\u00f3sticos de c\u00e1ncer nuevos disminuy\u00f3 un 21 % durante el confinamiento. Este estudio pretende ser una primera fotograf\u00eda de lo que ha supuesto la pandemia en la atenci\u00f3n hospitalaria a los pacientes oncol\u00f3gicos. La sombra de la [...] Tras el visto bueno de las autoridades sanitarias europeas, las campa\u00f1as de vacunaci\u00f3n podr\u00e1n empezar a partir del pr\u00f3ximo domingo en Europa continental, despu\u00e9s de Reino Unido y Estados Unidos. Un a\u00f1o despu\u00e9s de la aparici\u00f3n de la COVID-19, su ant\u00eddoto ya est\u00e1 disponible, pero todav\u00eda persisten m\u00faltiples interrogantes. El desarrollo y la introducci\u00f3n en [...] Las autoridades de Bolivia anunciaron que importar\u00e1n 1,6 millones de pruebas de ant\u00edgeno nasal para alternarlas con las de PCR (Reacci\u00f3n en Cadena de la Polimerasa) en los diagn\u00f3sticos masivos de la COVID-19. Estas son unas pruebas directas con un 95 por ciento de efectividad en la detecci\u00f3n de la enfermedad, explic\u00f3 en conferencia de [...] La Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT) de Argentina aprob\u00f3 el uso de un suero equino hiperinmune para el tratamiento de pacientes con la COVID-19 moderado o grave, anunci\u00f3 la empresa Inmunova que desarroll\u00f3 el m\u00e9todo. \"La aprobaci\u00f3n de este innovador medicamento con base en anticuerpos policlonales se basa en resultados positivos [...] Un nuevo estudio observacional internacional proporciona datos importantes sobre la seguridad de la cirug\u00eda de c\u00e1ncer de cabeza y cuello durante la pandemia de la COVID-19, seg\u00fan publican los investigadores en la edici\u00f3n en l\u00ednea de CANCER, la revista revisada por pares de la American Cancer Society. El estudio es parte de la COVIDSurg Collaborative, [...] Ambas vacunas presentan eficacias cercanas al 95 % y necesitan ser suministradas dos veces. No obstante, presentan algunas diferencias en cuanto a su conservaci\u00f3n. La de Moderna ha demostrado mayor capacidad para prevenir casos graves de la COVID-19, seg\u00fan datos publicados por los reguladores estadounidenses. Los reguladores farmac\u00e9uticos en Estados Unidos autorizaron la semana pasada [...] Uno de los principales micronutrientes que se sabe que tiene un posible efecto protector contra la enfermedad COVID-19 es la vitamina D, y por ello, cient\u00edficos de la universidad de North South University (Bangladesh) decidieron recopilar todas las investigaciones cient\u00edficas al respecto y establecer conclusiones siguiendo las recomendaciones Prisma (Preferred Reporting Items for Systematic reviews [...] |MEDIOS DE DIFUSI\u00d3N NACIONALES| La Habana, 24 dic (Prensa Latina) Cuba comenzar\u00e1 a exigir en enero de 2021 una prueba de PCR negativa para Covid-19 a los viajeros provenientes del extranjero, realizada por un laboratorio certificado en el pa\u00eds de origen. Dos nuevas variantes de SARS-nCov-2, el virus que causa la Covid-19, han encendido las alarmas en todo el mundo por sus caracter\u00edsticas inusuales que las hacen potencialmente m\u00e1s peligrosas que las que se conoc\u00edan hasta ahora Una brigada del Contingente Internacional de M\u00e9dicos Especializados en Situaciones de Desastres y Graves Epidemias Henry Reeve lleg\u00f3 por primera vez a Panam\u00e1 para enfrentar la pandemia de COVID-19, a solicitud del Gobierno de ese pa\u00eds. Una nueva mutaci\u00f3n del coronavirus, presuntamente procedente de Sud\u00e1frica, ha sido detectada en el Reino Unido, donde se han registrado dos casos de la nueva mutaci\u00f3n, seg\u00fan ha afirmado el secretario de Sanidad brit\u00e1nico, Matt Hancock. \"Hemos detectado dos casos de una variante m\u00e1s del coronavirus en el Reino Unido\". La Investigaci\u00f3n Nacional de Incidencia y Prevalencia de la infecci\u00f3n por SARS-COV-2, primera de su tipo en Cuba y en la regi\u00f3n de las Am\u00e9ricas, busca esclarecer seg\u00fan la doctora en Ciencias Vivian de las Mercedes Noriega Bravo, especialista de primer y segundo grado en Epidemiolog\u00eda, y jefa del equipo de investigadores algunas interrogantes sobre la COVID-19 |MEDIOS DE DIFUSI\u00d3N INTERNACIONALES| South Africa's health minister has rejected his British counterpart's claim that a new coronavirus variant in the country is more contagious or dangerous than a similar one in spreading the UK. \"At present, there is no evidence that the 501.V2 (variant) is more transmissible than the United Kingdom variant\u2014as suggested by the British Health Secretary,\" Zwelini Mkhize said in a statement published late Thursday. An experimental COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac is 91.25% effective, a Turkish health an infectious disease expert serving on Turkey's MONTEVIDEO (Sputnik) \u2014 Pese a que mucho se habla en estos d\u00edas sobre los planes de vacunaci\u00f3n contra el COVID-19 en Argentina, Chile, Brasil y M\u00e9xico, se ignora que los otros pa\u00edses de la regi\u00f3n m\u00e1s desigual del mundo, Am\u00e9rica Latina, no pueden contar la misma historia. This week, I was vaccinated against COVID-19 with the Pfizer mRNA vaccine, which brought to mind some frequently asked questions about the Pfizer and Moderna vaccines. New research involving scientists from Queen Mary University of London has found evidence of protective immunity in people up to four months after mild or asymptomatic COVID-19. The study, published today in Science Immunology, analyzed antibody and T cell responses workers who had mild or asymptomatic COVID-19 Z\u00daRICH, SUIZA (Sputnik) \u2014 Las pruebas existentes para detectar el coronavirus resultan efectivas para identificar la nueva mutaci\u00f3n del COVID-19, declar\u00f3 Frank Conings, experto del laboratorio de la Organizaci\u00f3n Mundial de la Salud (OMS), en una intervenci\u00f3n transmitida en las redes sociales. Recent analyses indicate that pregnant women severe cases COVID-19 following SARS-CoV-2 infection. New research led by investigators at Massachusetts General Hospital (MGH) and published in lower protective the placenta from mothers who are infected in the third trimester. The cause may be alterations to these antibodies after they're produced\u2014a process called glycosylation. Estados Unidos inform\u00f3 el lunes 191.000 nuevos casos de covid-19 y 1.700 nuevas muertes, mientras m\u00e1s de 115.000 personas fueron hospitalizadas ... Resalta que tambi\u00e9n se han visto las prote\u00ednas espiga del SARS-CoV-2 en las neuronas del cerebro de las autopsias de pacientes COVID-19 usando ... Z\u00daRICH, SUIZA (Sputnik) \u2014 Las mutaciones del coronavirus detectadas en el Reino Unido y Sud\u00e1frica son diferentes y no est\u00e1n relacionadas, afirm\u00f3 Maria Van Kerkhove, responsable de emergencias sanitarias de la Organizaci\u00f3n Mundial de la Salud (OMS). Severe allergy-like reactions in at least eight people who received the COVID-19 vaccine produced by Pfizer and BioNTech over the past 2 weeks may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccine's main ingredient, scientists say. A similar mRNA vaccine developed by Moderna, which was authorized for emergency use in the United States on Friday, also contains the compound, polyethylene glycol (PEG). Developers of the Russian coronavirus vaccine Sputnik V on Monday announced signing an agreement with AstraZeneca to test a combination of the British drugmaker's COVID-19 shots and a component of the vaccine created in Moscow. The developers of Sputnik V proposed the approach to AstraZeneca last month, suggesting it could increase the effectiveness of the British vaccine. The company announced on Dec. 11 a study to test the combination, and on Monday signed a memorandum of cooperation with Moscow-based medical research facility the Gamaleya Institute, the Russian Direct Investment Fund and Russian drugmaker R-Pharm. La inmunidad frente al SARS-CoV-2 -virus responsable de causar la enfermedad por COVID-19- es, casi un a\u00f1o despu\u00e9s de los "}